GSK (NYSE: GSK) expands Elizabeth McKee Anderson’s board committee roles

Rhea-AI Filing Summary

GSK plc reported a change in its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. She will serve on this committee in addition to her existing roles on the Audit & Risk and Remuneration committees.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 9 March 2026, London UK

Board Committee Change

GSK plc today announces the following change to its Board committee membership with effect from 9 March 2026:

Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. This appointment is in addition to her membership of the Audit & Risk and Remuneration committees.

V A Whyte

Company Secretary

9 March 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: March 09, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What board change did GSK (GSK) announce in March 2026?

GSK announced a change to its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson was appointed to the Corporate Responsibility Committee, expanding her responsibilities alongside existing roles on the Audit & Risk and Remuneration committees.

Who is Elizabeth McKee Anderson in relation to GSK (GSK)?

Elizabeth McKee Anderson is a GSK Board member serving on key committees. She already sits on the Audit & Risk and Remuneration committees and, effective 9 March 2026, has also joined the Corporate Responsibility Committee, broadening her governance role within the company.

Which GSK board committees does Elizabeth McKee Anderson serve on?

Elizabeth McKee Anderson serves on three GSK Board committees. She is a member of the Audit & Risk Committee, the Remuneration Committee, and, from 9 March 2026, the Corporate Responsibility Committee, reflecting a broad involvement in GSK’s oversight activities.

When did GSK’s new Corporate Responsibility Committee appointment take effect?

The appointment took effect on 9 March 2026. From that date, Elizabeth McKee Anderson became a member of GSK’s Corporate Responsibility Committee, in addition to her ongoing roles on the Audit & Risk and Remuneration committees within the company’s Board structure.

What type of company is GSK (GSK) according to this report?

GSK is described as a global biopharma company. Its stated purpose is to unite science, technology, and talent to get ahead of disease together, reflecting a focus on biopharmaceutical innovation and healthcare impact as outlined in the company description provided.

Who signed the March 2026 GSK Form 6-K report?

The report was signed by Victoria Whyte as an authorised signatory for GSK plc. She is identified as the Company Secretary, and her signature dated 9 March 2026 appears on behalf of the registrant under the Securities Exchange Act requirements.